1. Show article details.

    BRIEF-Gritstone Reports Second Quarter 2022 Financial Results And Provides Business Update

    Reuters – 5:22 PM ET 08/04/2022

    Gritstone bio Inc (GRTS): * GRITSTONE REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Gritstone bio Inc (GRTS) - QTRLY LOSS PER SHARE $0.34 Source text for Eikon: Further company coverage:

  2. Show article details.

    Gritstone Reports Second Quarter 2022 Financial Results and Provides Business Update

    GlobeNewswire – 4:05 PM ET 08/04/2022

    -- Clinical programs continue to progress, with initial data from Phase 2 study of “off the shelf” SLATE-KRAS and multiple studies within T cell-enhanced SARS-CoV-2 program expected this year -- -- Follow up data from subset of CORAL-BOOST study shows strong neutralizing antibody titers persisted without decay for at least 6 months after single boost administration of self-amplifying mRNA -- --...

  3. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022

    Benzinga – 10:31 AM ET 07/29/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  4. Show article details.

    BRIEF-Hercules Capital Reports Second Quarter 2022 Financial Results

    Reuters – 5:27 PM ET 07/28/2022

    Hercules Capital Inc (HTGC): * HERCULES CAPITAL REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS. * Hercules Capital Inc (HTGC) - QTRLY NET INVESTMENT INCOME OF $40.1 MILLION, OR $0.32 PER SHARE, AN INCREASE OF 8.6% Source text for Eikon: Further company coverage:

  5. Show article details.

    Hercules Capital Reports Second Quarter 2022 Financial Results

    Business Wire – 4:10 PM ET 07/28/2022

    Record 1H 2022 Total Gross Debt and Equity Commitments of $1.66 Billion Record 1H 2022 Gross Fundings of $790.7 Million Record 1H 2022 Net Debt Investment Portfolio Growth of $359.8 Million Record Q2 Total Gross Debt and Equity Commitments of $1.04 Billion Increased the Company’s Quarterly Base Cash Distribution to $0.35 per Share Increased Available Liquidity to over $775 Million Through a Ser...

  6. Show article details.

    Earnings Scheduled For July 28, 2022

    Benzinga – 6:06 AM ET 07/28/2022

      ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

  7. Show article details.

    Earnings Scheduled For July 28, 2022

    Benzinga – 5:06 AM ET 07/28/2022

      ** ArcelorMittal is estimated to report earnings for its second quarter. ** argenx is likely to report quarterly loss at $4.83 per share on revenue of $37.85 million. ** ASE Technology Holding Co is estimated to report quarterly earnings at $0.20 per share on revenue of $5.08 billion. ** Barclays is estimated to report earnings for its second quarter.

  8. Show article details.

    Earnings Preview For Hercules Capital

    Benzinga – 1:32 PM ET 07/27/2022

    Hercules Capital is set to give its latest quarterly earnings report on Thursday, 2022-07-28. Analysts estimate that Hercules Capital will report an earnings per share of $0.33. Hercules Capital bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

  9. Show article details.

    Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate

    Benzinga – 8:23 AM ET 07/26/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: U.K.'s Medicines and Healthcare products Regulatory Agency has approved Global Blood Therapeutics Inc's  Oxbryta for hemolytic anemia due to sickle cell disease in patients 12 and above. The approval comes for Oxbryta as monotherapy or in combination with hydroxycarbamide.

  10. Show article details.

    IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch

    Benzinga – 8:08 AM ET 07/26/2022

    IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch

  11. Show article details.

    Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank

    Business Wire – 6:30 AM ET 07/26/2022

    IVERIC bio, Inc. (ISEE) announced today that it has entered into a term loan debt financing facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.

  12. Show article details.

    BRIEF-Hercules Capital Increases Quarterly Cash Distribution To $0.35 Per Share

    Reuters – 6:06 AM ET 07/26/2022

    Hercules Capital Inc (HTGC): * HERCULES CAPITAL INCREASES ITS QUARTERLY CASH DISTRIBUTION TO $0.35 PER SHARE FOR THE SECOND QUARTER OF 2022 Source text for Eikon: Further company coverage:

  13. Show article details.

    Hercules Capital Announces Supplemental Cash Distribution of $0.15 per Share for the Second Quarter of 2022

    Business Wire – 6:03 AM ET 07/26/2022

    The Supplemental Cash Distribution of $0.15 per Share is in Addition to the Regular Quarterly Cash Distribution for the Second Quarter of 2022 of $0.35 per Share Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is p...

  14. Show article details.

    Hercules Capital Increases Its Quarterly Cash Distribution to $0.35 per Share for the Second Quarter of 2022

    Business Wire – 6:00 AM ET 07/26/2022

    Hercules Capital, Inc. (HTGC), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has increased and declared a second quarter 2022 cash distribution of $0.35 per share.

  15. Show article details.

    Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank

    GlobeNewswire – 4:05 PM ET 07/21/2022

    Gritstone bio, Inc. (GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced it has entered into an $80 million credit facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank.

  16. Show article details.

    Hercules Capital Announces Date for Release of Second Quarter 2022 Financial Results and Conference Call

    Business Wire – 6:00 AM ET 07/14/2022

    Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2022 financial results conference call for Thursday, July 28, 2022, at 2:00 p.m. PT.

  17. Show article details.

    Geron Corporation Announces Expansion of Existing Loan Facility

    Business Wire – 4:15 PM ET 06/30/2022

    Up to $50 Million in Additional Non-Dilutive Capital Potentially Available in 2023 Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.

  18. Show article details.

    What 4 Analyst Ratings Have To Say About Hercules Capital

    Benzinga – 10:40 AM ET 06/28/2022

    Analysts have provided the following ratings for Hercules Capital within the last quarter: These 4 analysts have an average price target of $17.88 versus the current price of Hercules Capital at $13.915, implying upside. Below is a summary of how these 4 analysts rated Hercules Capital over the past 3 months.

  19. Show article details.

    BRIEF-Hercules Capital Appoints DeAnne Aguirre To Board Of Directors

    Reuters – 6:24 AM ET 06/24/2022

    Hercules Capital Inc (HTGC): * HERCULES CAPITAL ANNOUNCES THE APPOINTMENT OF MS. DEANNE AGUIRRE TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

  20. Show article details.

    Hercules Capital Announces the Appointment of Ms. DeAnne Aguirre to Its Board of Directors

    Business Wire – 6:00 AM ET 06/24/2022

    Hercules Capital, Inc. (HTGC), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022.

Page:

Today's and Upcoming Events

  • Oct
    26

    HTGC to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    08

    HTGC ex-Dividend for $0.35 on 08/08/2022

    • Announce Date: 07/26/2022
    • Record Date: 08/09/2022
    • Pay Date: 08/16/2022
  • Aug
    08

    HTGC ex-Dividend for $0.15 on 08/08/2022

    • Announce Date: 07/26/2022
    • Record Date: 08/09/2022
    • Pay Date: 08/16/2022
  • Jul
    28

    HTGC announced Q2 earnings.

  • May
    16

    HTGC ex-Dividend for $0.15 on 05/16/2022

    • Announce Date: 05/03/2022
    • Record Date: 05/17/2022
    • Pay Date: 05/24/2022
  • May
    16

    HTGC ex-Dividend for $0.33 on 05/16/2022

    • Announce Date: 05/03/2022
    • Record Date: 05/17/2022
    • Pay Date: 05/24/2022
Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.